Aethlon Medical Shares Surge 54% After DSMB Nod in Hemopurifier Trial

Overview

Aethlon Medical Inc (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. The company’s lead product, the Hemopurifier®, is a lectin-based immunotherapeutic device designed to remove cancer-promoting exosomes and circulating viruses from the bloodstream. The U.S. Food and Drug Administration (FDA) has designated the Hemopurifier® as a Breakthrough Device for:

• treatment of individuals with advanced or metastatic cancer who are unresponsive or intolerant to standard therapies, and
• removal of life-threatening viruses not addressed by approved treatments.

Ticker	Exchange	Price (USD)	Change (%)	Volume
AEMD	NAS	1.7098	+54.04	6,717,790

Corporate Structure

Founded in 1999, Aethlon Medical employs between 11 and 50 staff members in various functions including research and development, clinical operations, and regulatory affairs. The executive team is led by Chief Executive Officer James Frakes and Chief Medical Officer Steven LaRosa. The company collaborates with ReSQ Clinical Research for trial management.

Hemopurifier by Harper Sunday

Recent Developments

• The Hemopurifier® is currently undergoing a safety, feasibility, and dose-finding trial in cancer patients receiving anti-PD-1 therapies (pembrolizumab or nivolumab) in Australia and India. Each country’s trial cohort is expected to enroll approximately nine to 18 patients, with safety as the primary endpoint.
• The independent Data Safety Monitoring Board (DSMB) has recommended proceeding to the next patient cohort in the Australian oncology trial following a scheduled review of safety data.
• The first patient was treated at Royal Adelaide Hospital under the Australian clinical trial protocol.
• On October 30, 2024, Aethlon Medical’s CEO and CMO presented an update at the Virtual Emerging Growth Conference regarding trial progress and development strategy.

Financial and Strategic Analysis

Aethlon Medical’s share price increased by 54.04% as of August 21, 2025, reflecting investor interest in its Breakthrough Device designation and clinical milestones. Trading volume surpassed 6.7 million shares, indicating active market participation. The company’s focus on non-pharmacologic immunotherapy distinguishes it from competitors in oncology and infectious disease markets. Ongoing trials and the FDA’s breakthrough status may provide pathways for accelerated review.

Market Position and Industry Context

Within the medical equipment manufacturing sector, Aethlon Medical is positioned at the intersection of oncology and viral therapeutics. The Hemopurifier® employs a mechanism of physical removal of pathological particles, distinguishing it from biologics and small-molecule treatments. Unlike many industry peers that focus on single indications, Aethlon Medical's approach addresses both advanced cancer and viral infections, potentially expanding its clinical relevance. Regulatory designations and cross-border clinical programs highlight the device’s competitive positioning.

tl;dr

As of August 21, 2025, Aethlon Medical’s shares trade at $1.7098 following a 54.04% one-day increase on volume exceeding 6.7 million. The company has advanced its Hemopurifier® oncology trial in Australia, receiving a positive DSMB recommendation to proceed with the next cohort, and has initiated first-patient treatment at Royal Adelaide Hospital. A presentation at the October 30, 2024, Virtual Emerging Growth Conference detailed development milestones. Upcoming catalysts include additional cohort enrollments in Australia and India, interim safety data release, and ongoing engagement with U.S. and international regulatory agencies.